CompaniesCardinal HealthLatest from Cardinal HealthMolecular ImagingIMV: PET scan volumes continue to growBy Davin KorstjensThe total volume of PET scans increased 10.2% year over year in 2023, according to the newly published IMV 2024 PET Market Summary Report.March 7, 2024Nuclear MedicineCardinal Health to feature tech, therapy dogs at SNMMI boothBy AuntMinnie.com staff writersCardinal Health Nuclear & Precision Health Solutions plans to showcase its Nuctrac theranostic module at the upcoming Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2023 annual meeting in Chicago.June 21, 2023Radiation Oncology/TherapyNavidea secures $7.5M from Cardinal HealthBy AuntMinnie.com staff writersImmunodiagnostics and immunotherapy drug developer Navidea Biopharmaceuticals has secured $7.5 million from Cardinal Health in lieu of a milestone payment.June 18, 2023Molecular ImagingRLS appoints new director of regulatory affairsBy AuntMinnie.com staff writersRadioisotope Life Sciences (RLS), a U.S.-based nuclear pharmacy network, recently appointed Glenn Sullivan, PhD, as the company's director of regulatory affairs.June 13, 2023Molecular ImagingIMV: PET prostate scan volumes saw robust growth in 2022By Davin KorstjensPET prostate scan volumes grew 46% year-over-year, showing an increase of 3 percentage points to produce 9% of the overall procedure mix by study type, according to the newly published IMV 2023 PET Market Summary Report.March 20, 2023Nuclear MedicineNavidea reports revenue declines in Q4, all of 2021By AuntMinnie.com staff writersRadiopharmaceutical developer Navidea Biopharmaceuticals reported a decline in revenues for the fourth quarter of 2021 and the entire year.March 22, 2022Nuclear MedicineFDA clears Cardinal's Lymphoseek for pediatric useBy AuntMinnie.com staff writersCardinal Health announced that its Lymphoseek radiopharmaceutical has been approved for pediatric use by the U.S. Food and Drug Administration (FDA).June 10, 2021Radiation Oncology/TherapyViewRay's COO to step downBy AuntMinnie.com staff writersThe chief operating officer (COO) of image-guided radiation therapy vendor ViewRay is leaving the company effective March 31.March 14, 2021Nuclear MedicineNavidea gets 5-year patent extension for LymphoseekBy AuntMinnie.com staff writersRadiopharmaceutical developer Navidea Biopharmaceuticals has received a five-year patent extension for its Lymphoseek radiopharmaceutical.March 19, 2020Molecular ImagingIMV: PET scan volume continues growing at steady paceBy Lorna YoungProcedure volume in the PET market is continuing to grow at about 6% per year in the U.S. since 2013, reaching its highest level ever in the U.S. in 2019, according to a new report by IMV Medical Information Division.March 9, 2020Nuclear MedicineNavidea gets patent extension for LymphoseekBy AuntMinnie.com staff writersRadiopharmaceutical developer Navidea Biopharmaceuticals has received a patent extension for its Lymphoseek radiopharmaceutical.December 6, 2018Nuclear MedicineCardinal Health joins SNMMI's Value InitiativeBy AuntMinnie.com staff writersRadiopharmaceutical supplier Cardinal Health has joined the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) Value Initiative Industry Alliance.November 13, 2018Nuclear MedicineCardinal Health taps new head of pharmaceutical unitBy AuntMinnie.com staff writersRadiopharmaceutical supplier Cardinal Health has hired Victor Crawford to be the CEO of its pharmaceutical segment, effective November 12.October 15, 2018Practice ManagementStrategic Radiology adds Fremer to ranksBy AuntMinnie.com staff writersRadiology consortium Strategic Radiology has hired Sharon Fremer as vice president of revenue cycle optimization. Fremer will lead an organization-wide revenue cycle optimization program aimed at identifying and driving best practices implementation.September 12, 2018Nuclear MedicineNorthStar's novel generator could relieve U.S. isotope shortagesBy Wayne ForrestNorthStar Medical Radioisotopes is hoping that its isotope separation technology -- almost a decade in the making -- can alleviate worries about inadequate sources of molybdenum-99, the precursor to technetium-99m, a widely used radiopharmaceutical for nuclear medicine scans.March 28, 2018
